In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across...
Continue Reading
In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models...
Continue Reading
In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging...
Continue Reading
Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models...
Continue Reading
Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared...
Continue Reading
Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic...
Continue Reading
KRAS mutant proteins that drive cancer development are highly similar in sequence and structure. Direct inhibitors are most likely to...
Continue Reading
Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including: In vitro induced Palbociclib resistant MCF-7 cell line...
Continue Reading
